ATRS Antares Pharma Inc.

2.72
+0.2  (+8%)
Previous Close 2.52
Open 2.55
Price To Book 8.24
Market Cap 450,324,291
Shares 165,560,401
Volume 1,694,883
Short Ratio
Av. Daily Volume 1,711,315
Stock charts supplied by TradingView

NewsSee all news

  1. Antares Pharma Reports Fourth Quarter and Full Year 2019 Operating and Financial Results

    Record Quarterly Revenue of $37.8 Million – Earnings Per Share of $0.03 Record Annual Revenue of $123.9 Million, a 95% Increase over 2018 Annual Revenue EWING, N.J., March 03, 2020 (GLOBE NEWSWIRE) -- Antares Pharma,

  2. Antares Pharma to Present at the Cowen and Company 40th Annual Health Care Conference

    EWING, N.J., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Cowen and Company 40th Annual Health

  3. Antares Pharma to Report Fourth Quarter and Full Year 2019 Financial and Operating Results

    EWING, N.J., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced it will release its fourth quarter and full year 2019 financial results and recent operating progress before the market

  4. Antares Pharma Announces Full-Year 2020 Net Revenue Guidance Range of $135 to $155 Million

    EWING, N.J., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (The Company) today announced 2020 full-year net revenue guidance of $135 to $155 million, which includes a range of potential revenue

  5. Antares Pharma Social Media Campaign for XYOSTED® Wins MarCom Platinum Award

    EWING, N.J., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("Antares") ("the Company") today announced that the Company's social media campaign for XYOSTED®, has been honored with a 2019 MarCom

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approved December 8, 2011.
Anturol
Overactive bladder
Approved Oct 14, 2013.
OTREXUP
Rheumatoid arthritis (RA)
Approval announced February 14, 2018.
Makena - auto injector
Reduce the risk of preterm birth in women with a singleton pregnancy
FDA Approval announced October 1, 2018.
XYOSTED (testosterone enanthate)
Testosterone deficiency
Phase 2 trial planned for 2020.
Selatogrel and QuickShot
Acute myocardial infarction (AMI)

Latest News

  1. Antares Pharma Reports Fourth Quarter and Full Year 2019 Operating and Financial Results

    Record Quarterly Revenue of $37.8 Million – Earnings Per Share of $0.03 Record Annual Revenue of $123.9 Million, a 95% Increase over 2018 Annual Revenue EWING, N.J., March 03, 2020 (GLOBE NEWSWIRE) -- Antares Pharma,

  2. Antares Pharma to Present at the Cowen and Company 40th Annual Health Care Conference

    EWING, N.J., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Cowen and Company 40th Annual Health

  3. Antares Pharma to Report Fourth Quarter and Full Year 2019 Financial and Operating Results

    EWING, N.J., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced it will release its fourth quarter and full year 2019 financial results and recent operating progress before the market

  4. Antares Pharma Announces Full-Year 2020 Net Revenue Guidance Range of $135 to $155 Million

    EWING, N.J., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (The Company) today announced 2020 full-year net revenue guidance of $135 to $155 million, which includes a range of potential revenue

  5. Antares Pharma Social Media Campaign for XYOSTED® Wins MarCom Platinum Award

    EWING, N.J., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("Antares") ("the Company") today announced that the Company's social media campaign for XYOSTED®, has been honored with a 2019 MarCom

  6. Antares Pharma to Present at the 31st Annual Piper Jaffray Healthcare Conference

    EWING, N.J., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the 31st Annual Piper Jaffray Healthcare

  7. Antares Pharma Enters Into a Global Development Agreement With Idorsia Pharmaceuticals Ltd.

    EWING, N.J., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("Antares") today announced that it has entered into a global agreement with Idorsia Pharmaceuticals Ltd. ("Idorsia") (SIX: IDIA) to

  8. Idorsia enters into a collaboration with Antares for the development of a novel self-administered drug-device product for selatogrel

    • The companies will develop a novel drug-device product combining Idorsia's P2Y12 receptor antagonist, selatogrel, with the Antares QuickShot® auto-injector • Idorsia is preparing for a Phase 3 study to

  9. Antares Pharma to Present at the Jefferies 2019 London Healthcare Conference

    EWING, N.J., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Jefferies 2019 London Healthcare

  10. Antares Pharma Reports Third Quarter 2019 Operating and Financial Results

    Record Quarterly Revenue of $34.3 Million – Earnings Per Share of $0.01 The Company Increases Full Year 2019 Revenue Guidance to a Range of $115.0 to $120.0 Million EWING, N.J., Nov. 05, 2019 (GLOBE NEWSWIRE) --

  11. Antares Pharma Announces Receipt of Final Payment From Sale of Zomajet™ Needle-Free Delivery System

    EWING, N.J., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("Antares" or "Company") today announced that it has received the final payment of $2.5 million from Ferring Pharmaceuticals ("Ferring")

  12. Antares Pharma to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    EWING, N.J., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Ladenburg Thalmann 2019 Healthcare